World Health Organization Issues Warning Over Critical Lack of Obesity Jabs
Under a tenth of patients who could benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it publishes its initial guidance on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is calling for broader and more equitable availability to this class of drugs.
Based on projections, over two billion will be obese by 2030 without intervention.
"The latest guidance recognises that obesity is a chronic disease that can be addressed with thorough and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key hurdles to universal availability to the jabs that can assist patients in reducing substantial body mass, says the organization.
Weight-Loss Drug Scarcity
Despite the present most favorable outlook, the supply of these medications would only suffice for about 100 million people – under 10% of those who need them, according to the health organization.
The recommendation encourages nations and manufacturers to widen availability, via measures including patent sharing.
A patent on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in several nations in 2026.
How Weight-Loss Injections Function
GLP-1 drugs imitate a natural hormone to delay gastric emptying, curb appetite and boost the sense of being full so individuals reduce food intake.
Patients typically see weight reduction within a few weeks of commencing the weekly injections.
Studies points to users may see weight return within a year of stopping the medication, as their normal appetite return.
To be carrying excess weight elevates your likelihood for contracting diseases, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight affects individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, per the health agency.
